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Danaparoid has recently received attention as probably the
best available alternative to heparin for patients with
heparin-induced thrombocytopenia and thrombosis (HITT).
Danaparoid anticoagulation for operations performed with
cardiopulmonary bypass (CPB), however, is not without its
problems. In this case report we describe the failure of dana-
paroid anticoagulation for a patient scheduled to undergo
redo coronary artery revascularization and aortic valve
replacement. 
Clinical summary. A 68-year-old man weighing 76 kg
was being treated with unfractionated heparin for unstable
angina when HITT developed. The patient was scheduled for
surgery when an abrupt fall in platelet count from 115,000 to
67,000 over a 48-hour period was identified while he was
receiving heparin therapy. The diagnosis of HITT was con-
firmed by a heparin-induced platelet activation assay, and the
decision was made to use danaparoid anticoagulation for the
management of this patient’s unstable angina.
Before the beginning of the operation, intravenous apro-
tonin was administered because this was standard antifibri-
nolytic therapy at our institution for reoperations to minimize
postoperative blood loss. A 7500 IU (100 IU/kg) load of
danaparoid was given intravenously and an infusion was
started at 533 IU per hour (7 IU · kg–1 · h–1). Within a half
hour of initiating the danaparoid, the presence of small fibrin
strands in pericardium prompted the administration of 2 addi-
tional 1500 IU boluses and an increase in the background
infusion rate to 760 IU per hour. The further accumulation of
clot in the operative field prompted the surgeon to perform a
left anterior descending coronary artery anastomosis off CPB
and to abandon the valve replacement procedure. Unfortu-
nately, at the end of the operation a 4-mm ST-segment eleva-
tion occurred in lead V5, presumably because of blood clot
formation in the artery during the anastomosis. The patient
was transferred to the surgical intensive care unit, where
immediate recovery was complicated by persistent ST-seg-
ment elevation and some central chest discomfort on awak-
ening. A perioperative myocardial infarction was diagnosed.
The patient eventually recovered and was discharged to his
home. He awaits valve replacement surgery once platelet-
bound antibodies to heparin disappear. 
Discussion. A number of alternatives to heparin for use dur-
ing CPB surgery have been suggested for patients with HITT,
such as ancrod, iloprost, and danaparoid. Numerous short-
comings, however, have been identified with ancrod and ilo-
prost in this setting. The clinical usefulness of danaparoid dur-
ing CPB is limited by the lack of a rapid method for
monitoring the adequacy of anticoagulation, lack of a reversal
agent, and a very long elimination half-life, which makes it
extremely difficult to titrate. Significant postoperative bleed-
ing has been identified with the use of danaparoid for cardiac
operations. The recommended therapeutic antifactor Xa level
for CPB is between 1.5 and 2 U/mL.1 Interestingly, dana-
paroid exerts its antifactor Xa activity without noticeable
effects on other blood coagulation parameters and thus cannot
be monitored by routine testing procedures, such as activated
partial thromboplastin times and activated clotting times.1
We had initially selected the danaparoid regimen of
Westphal and coworkers2 of 100 IU/kg (7500 IU) with a con-
tinuous infusion of 7 IU · kg–1 · h–1 (533 IU/h).2 The use of a
continuous infusion was believed to be optimal, since bypass
time for the procedure was anticipated to be longer than 1
hour, and in the absence of antifactor Xa monitoring, sole
anticoagulant therapy with intermittent boluses of the drug
would be impractical. In the 2 hours of trying to establish an
anticoagulated state for CPB and in the performance of a left
anterior descending coronary artery anastomosis off CPB,
our patient received a cumulative dose of about 12,000 IU (ie
158 IU/kg) of danaparoid.
The currently recommended protocol is a 125 IU/kg intra-
venous bolus, with 3 IU/mL in the priming fluid, and an intra-
venous infusion of 7 IU · kg–1 · h–1.3 The infusion is to be start-
ed at the time of bypass hook-up and stopped about 45 to 60
minutes before the anticipated completion of CPB. This pro-
tocol does not presently recommend antifactor Xa monitoring.
The failure of danaparoid anticoagulation for this patient may
have been due to inadequate loading with this agent from an
overestimation of the contribution of its preoperative use.
However, the 12,000 IU danaparoid cumulative exposure over
2 hours had no preventive effect on fibrin generation. Note
that with the long elimination half-life of danaparoid (ie, anti-
coagulant activity) of around 24 hours,1 little activity would
have been lost over the 2-hour titration period. It is possible
that a crossover reaction from heparin to danaparoid-induced
thrombocytopenia and thrombosis may have developed.1
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However, the patient’s platelet count continued to rise well
after the discontinuation of heparin and institution of dana-
paroid, making this possibility less likely. An interaction with
the antifibrinolytic agent aprotonin was also hypothesized;
however, Wilhelm and colleagues4 reported a successful,
albeit single, case of danaparoid use in a patient concurrently
receiving aprotonin. It could be that after fibrin clot starts to
form, no amount of danaparoid will reverse this in the pres-
ence of the antifibrinolytic action of aprotinin. Tachyphylaxis
to danaparoid might also have been a possibility, especially
since the man had received the drug for 6 days before the oper-
ation and heparin by continuous infusion for 5 days before
that. Prolonged use of these agents before the procedure could
have depleted his antithrombin III stores and thus made him
relatively resistant to danaparoid anticoagulation.5
Conclusions. Danaparoid may be a useful alternative to
heparin in patients with HITT undergoing CPB procedures.
However, a number of concerns are raised by this report. The
inability to monitor antifactor Xa levels in the operating room
makes this form of anticoagulation troublesome. Caution
would be advised when using danaparoid for CPB in patients
who are concurrently receiving the antagonist to fibrinolysis,
aprotonin. Vigilance as well would be advised in patients who
had received prolonged infusions of either heparin or dana-
paroid before cardiac surgery, since they may be more resis-
tant to surgical anticoagulation.
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